1-5 of 5
Philip Rowlings
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response

Jorge E. Cortes, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD, Neil P. Shah, MD, PhD, Jiri Mayer, MD, PhD, Philip Rowlings, MD, Hirohisa Nakamae, MD, PhD, M. Brigid Bradley-Garelik, MD, Hesham Mohamed, MD, Hagop M. Kantarjian, MD, Giuseppe Saglio, MD
Journal: Blood
Blood (2013) 122 (21): 653.
https://doi.org/10.1182/blood.V122.21.653.653
Published: 2013
Journal Articles

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Michael P Osborn, Susan Branford, PhD, Deborah L White, PhD, John F Seymour, PhD, Ruth Columbus, Kerry Taylor, Christopher Arthur, Anthony Schwarer, Julian Cooney, MD, Michael F Leahy, Philip Rowlings, John Catalano, MD, Mark S Hertzberg, MD, PhD, Robin Filshie, PhD, Anthony K Mills, Keith Fay, Simon Durrant, Henry Januszewicz, David Joske, MD, Craig Underhill, Scott Dunkley, PhD, Andrew Grigg, Timothy P Hughes, MD
Journal: Blood
Blood (2009) 114 (22): 1125.
https://doi.org/10.1182/blood.V114.22.1125.1125
Published: 2009
Journal Articles

Dasatinib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Study.

Thierry Facon, Xavier Leleu, A. Keith Stewart, MD, Andrew Spencer, Philip Rowlings, Cyrille Hulin, Michel Attal, Felix Garzon, MD, PhD, Eric Bleickardt, Konstantina Gialelis, Doreen Tuozzoli, Dominique Derreumaux, Pieter Sonneveld
Journal: Blood
Blood (2009) 114 (22): 1876.
https://doi.org/10.1182/blood.V114.22.1876.1876
Published: 2009
Journal Articles

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Clinical Trials & Observations
Timothy P. Hughes, Susan Branford, Deborah L. White, John Reynolds, Rachel Koelmeyer, John F. Seymour, Kerry Taylor, Chris Arthur, Anthony Schwarer, James Morton, Julian Cooney, Michael F. Leahy, Philip Rowlings, John Catalano, Mark Hertzberg, Robin Filshie, Anthony K. Mills, Keith Fay, Simon Durrant, Henry Januszewicz, David Joske, Craig Underhill, Scott Dunkley, Kevin Lynch, Andrew Grigg
Journal: Blood
Blood (2008) 112 (10): 3965–3973.
https://doi.org/10.1182/blood-2008-06-161737
Published: 2008
Includes: Supplemental data
Journal Articles

Treatment of Autoimmune Disease by Intense Immunosuppressive Conditioning and Autologous Hematopoietic Stem Cell Transplantation

Richard K. Burt, Ann E. Traynor, Richard Pope, James Schroeder, Bruce Cohen, Karyn H. Karlin, Lorri Lobeck, Charles Goolsby, Philip Rowlings, Floyd A. Davis, Dusan Stefoski, Cass Terry, Carolyn Keever-Taylor, Steve Rosen, David Vesole, Maryanne Fishman, Mary Brush, Salim Mujias, Marcelo Villa, William H. Burns
Journal: Blood
Blood (1998) 92 (10): 3505–3514.
https://doi.org/10.1182/blood.V92.10.3505
Published: 1998